Hospital-acquired pneumonia (HAP) is an acute inflammatory disease of the lung tissue that occurs in patients in a healthcare facility, particularly in a hospital. This form of pneumonia is most often associated with exposure to pathogens released from the environment, including microorganisms such as Streptococcus pneumoniae, Staphylococcus aureus, and gram-positive and gram-negative flora. Due to the characteristics of the hospital environment and the health status of patients, HAP has its own specific clinical picture, predisposing factors, and treatment methods that require increased attention from medical personnel. The high level of morbidity and mortality among this group of patients makes HAP one of the main problems of modern healthcare, requiring an integrated approach to diagnosis and treatment.
History of the disease and interesting historical facts
Hospital-acquired pneumonia as a medical problem was first described in the medical literature of the 20th century, but cases of inflammatory lung diseases developing in hospital settings have been known for a long time. In the 1940s, with the development of antibiotics, the incidence of bacterial forms of pneumonia decreased significantly, but with the emergence of antibiotic-resistant strains, such as methicillin-resistant Staphylococcus aureus (MRSA), the situation worsened again. Clinical studies indicate that BP can occur in 5-10% hospitalized patients, which requires additional research in the field of prevention and treatment. Interestingly, in some cases, BP has been detected in patients undergoing rehabilitation after surgical interventions, which further emphasizes the importance of infection control in healthcare settings.
Epidemiology
The epidemiology of hospital-acquired pneumonia is characterized by high morbidity among various patient groups in hospitals. According to the World Health Organization, up to 300 cases of hospital-acquired pneumonia are registered annually per 1000 hospitalized patients. At the same time, the incidence increases significantly in critically ill patients in intensive care units, where it can reach 20-30%. It is also necessary to take into account that hospital-acquired pneumonia is associated with high mortality, which ranges from 20 to 50% depending on the patient's health condition, the presence of concomitant diseases and the timeliness of the start of therapy. This emphasizes the importance of early diagnosis and effective treatment of this disease.
Genetic predisposition to this disease
Genetic predisposition to hospital-acquired pneumonia remains a subject of research, but scientists are now identifying a couple of key genes that may be associated with susceptibility to the disease. For example, the TLR4 gene, which is responsible for recognizing pathogens, shows increased activity in patients with frequent respiratory infections. Studying mutations in genes responsible for the immune response, such as IL-6, may also shed light on the mechanisms of predisposition. However, further genetic studies and more in-depth data analysis are needed to draw definitive conclusions.
Risk factors for the development of this disease
Risk factors for PD are varied and may include both physical and chemical aspects. The main risk factors include:
- Immunodeficiency states (eg, HIV, diseases that cause suppression of the immune system).
- Chronic lung diseases such as chronic obstructive pulmonary disease (COPD) and asthma.
- Older age, especially when combined with cognitive impairment or frailty.
- The presence of invasive medical devices (eg, intubation, catheters) that increase the risk of infection.
- Insufficient hygiene and infection control in healthcare settings.
Chemical risk factors include:
- Contact with toxic substances and chemical reagents that can irritate the mucous membrane of the respiratory tract.
- Aspiration of gastric contents, which often occurs in patients with impaired consciousness.
Diagnosis of this disease
Diagnosis of hospital-acquired pneumonia is based on a combination of clinical presentation and additional investigations. The main symptoms include:
- Cough with discharge (often purulent).
- Fever and chills.
- Dyspnea and shortness of breath.
- Chest pain when breathing or coughing.
Laboratory tests, such as a complete blood count, may show elevated white blood cell count and C-reactive protein. Radiologic studies, including chest radiography, may reveal infiltration and other changes consistent with pneumonia. Microbiologic examination of the airways and, if necessary, bronchoalveolar lavage are also important to determine the etiology of the disease. Differential diagnosis should include other pulmonary diseases, including tuberculosis and lung cancer.
Treatment
Treatment of hospital pneumonia requires a comprehensive approach, including both conservative and surgical methods. General principles of treatment are as follows:
- Taking antibiotics based on the sensitivity of the isolated microorganisms.
- Supportive care including hydration and oxygen therapy.
- Physiotherapy procedures to improve bronchial drainage.
Pharmacological treatment includes:
- Antibiotics: penicillins, cephalosporins, macrolides.
- Bronchodilators to relieve bronchospasm.
- Steroids for severe inflammation.
In cases of complications such as lung abscesses, surgery may be required, including drainage or lung resection. Other treatments may also be available, including mucolytics and mucus thinners.
List of medications used to treat this disease
Among the prescribed medications, the following can be distinguished:
- Penicillins: Amoxiclav, Penicillin.
- Cephalosporins: Ceftriaxone, Cefotaxime.
- Macrolides: Azithromycin, Clarithromycin.
- Tetracyclines: Doxycycline.
- Antibiotics for the treatment of MRSA: Vancomycin, Linezolid.
Disease monitoring
Monitoring the condition of a patient with PD includes regular control studies, such as:
- Examination for worsening or improvement of clinical symptoms.
- Lab tests to monitor inflammatory markers and electrolytes.
- Radiological examinations to monitor the dynamics of changes in the lungs.
The prognosis with early diagnosis and adequate therapy is favorable, but possible complications such as abscesses and pleurisy may require prolonged treatment or surgery, which negatively affects the overall outcome.
Age-related features of the disease
Hospital-acquired pneumonia has its own characteristics in different age groups. In children, BP often develops against the background of concomitant infections and can manifest itself with more pronounced toxicity. In the elderly, pneumonia often occurs atypically, which contributes to a delay in diagnosis. In addition, the presence of concomitant diseases, such as diabetes or cardiovascular diseases, increases the risk of severe BP in the older age category.
Questions and Answers
- What are the key symptoms of hospital-acquired pneumonia? The main symptoms include cough with purulent sputum, fever, chills and shortness of breath.
- What are the risk factors for hospital-acquired pneumonia? Risk factors include age over 65 years, chronic diseases and the use of invasive technical means.
- How is hospital-acquired pneumonia diagnosed? Diagnosis includes clinical examination, chest X-ray, and laboratory tests of blood and sputum.
- How is hospital pneumonia treated? Treatment involves antibiotic therapy, supportive care and, if necessary, surgery.
- What are the possible complications of hospital-acquired pneumonia? Possible complications include pleurisy, lung abscesses, and sepsis.
Advice from Dr. Oleg Korzhikov
Given the current problem of hospital pneumonia, Dr. Oleg Korzhikov highlights several key aspects that are worth paying attention to:
- Regularly taking preventive measures such as pneumococcal and influenza vaccinations.
- Timely diagnosis and treatment of any infections, especially in high-risk patients.
- Please pay attention to compliance with hygiene regimes in medical institutions and personal hygiene.
- If you have symptoms, see a doctor immediately to rule out pneumonia.
The doctor emphasizes that prevention and early intervention play a decisive role in the favorable outcome of hospital-acquired pneumonia treatment.
